Zura Bio (NASDAQ:ZURA) Trading 17.2% Higher – Should You Buy?

Shares of Zura Bio Limited (NASDAQ:ZURA) were up 17.2% during trading on Friday . The stock traded as high as $5.25 and last traded at $5.32. Approximately 985,066 shares were traded during trading, an increase of 34% from the average daily volume of 737,134 shares. The stock had previously closed at $4.54.

Analysts Set New Price Targets

A number of research firms recently weighed in on ZURA. Oppenheimer lowered their target price on shares of Zura Bio from $16.00 to $15.00 and set an “outperform” rating on the stock in a research note on Friday, March 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Zura Bio in a research report on Wednesday, April 8th. Finally, Chardan Capital upped their price objective on Zura Bio from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, March 23rd. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.75.

Zura Bio Trading Up 17.8%

The stock has a market capitalization of $507.61 million, a P/E ratio of -4.91 and a beta of 0.03. The company has a 50-day moving average price of $4.47 and a 200 day moving average price of $5.25.

Zura Bio (NASDAQ:ZURA) last posted its earnings results on Thursday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.05). As a group, research analysts expect that Zura Bio Limited will post -0.76 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Allworth Financial LP acquired a new stake in Zura Bio in the fourth quarter valued at approximately $30,000. Scientech Research LLC purchased a new stake in shares of Zura Bio during the 3rd quarter valued at $45,000. AQR Capital Management LLC purchased a new stake in shares of Zura Bio during the 1st quarter valued at $72,000. Bank of America Corp DE boosted its position in shares of Zura Bio by 31.9% in the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock worth $103,000 after purchasing an additional 9,966 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in shares of Zura Bio in the 3rd quarter worth $109,000. Institutional investors own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.